PD-L1-negative triple-negative breast cancer exhibited a remarkable response to cadonilimab: a case report

Breast cancer, a prevalent malignancy among women, is primarily categorized into four subtypes based on immunohistochemistry: luminal A breast cancer, luminal B breast cancer, HER2-enriched breast cancer, and triple-negative breast cancer (TNBC). Molecular targets for TNBC therapy are lacking, and T...

Descripció completa

Dades bibliogràfiques

Autors principals:	Baohua Chen, Yuanyuan Jia, Lingjun Meng, Nanjun Hu
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-03-01
Col·lecció:	Frontiers in Oncology
Matèries:	cadonilimab CTLA-4 immunotherapy PD-1 triple-negative breast cancer (TNBC)
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1764908/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!